Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

2.4K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.4K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.7K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

5.0K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of localized and general fatigue on postural adjustments coupling during predictable external perturbations.

European journal of applied physiology·2025
Same author

Modelling inflammation-induced peripheral sensitization in a dish-more complex than expected?

Pain·2025
Same author

The Different Phytochemical Profiles of <i>Salvia officinalis</i> Dietary Supplements Labelled for Menopause Symptoms.

Molecules (Basel, Switzerland)·2024
Same author

A potassium channel agonist protects hearing function and promotes outer hair cell survival in a mouse model for age-related hearing loss.

Cell death & disease·2022
Same author

Postural Threat Influences the Coupling Between Anticipatory and Compensatory Postural Adjustments in Response to an External Perturbation.

Neuroscience·2022
Same author

Discovery of Novel TRPM8 Blockers Suitable for the Treatment of Somatic and Ocular Painful Conditions: A Journey through p<i>K</i><sub>a</sub> and LogD Modulation.

Journal of medicinal chemistry·2021

Related Experiment Video

Updated: May 2, 2026

Monitoring ER/SR Calcium Release with the Targeted Ca2+ Sensor CatchER+
12:30

Monitoring ER/SR Calcium Release with the Targeted Ca2+ Sensor CatchER+

Published on: May 19, 2017

14.2K

Ca(2+) release-activated Ca(2+) channel inhibitors.

Paolo Pevarello1, Silvia Cainarca, Chiara Liberati

  • 1Axxam Discovery Chemistry, Via Castellino, 111, 80100 Napoli, Italy.

Pharmaceutical Patent Analyst
|March 5, 2014
PubMed
Summary

Calcium release-activated calcium (CRAC) channels are key therapeutic targets for immune, allergic, and cancer diseases. This review analyzes patents on CRAC channel inhibition, highlighting growing research interest.

More Related Videos

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels
07:17

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels

Published on: December 13, 2024

2.0K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.4K

Related Experiment Videos

Last Updated: May 2, 2026

Monitoring ER/SR Calcium Release with the Targeted Ca2+ Sensor CatchER+
12:30

Monitoring ER/SR Calcium Release with the Targeted Ca2+ Sensor CatchER+

Published on: May 19, 2017

14.2K
Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels
07:17

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels

Published on: December 13, 2024

2.0K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.4K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Calcium release-activated calcium (CRAC) channels are crucial for cellular functions.
  • Dysregulation of CRAC channels is implicated in immunological, allergic, and cancerous diseases.
  • CRAC channels are emerging as significant therapeutic targets.

Purpose of the Study:

  • To review and analyze patents related to CRAC channel inhibition.
  • To discuss the biological methods employed in CRAC channel inhibition patents.
  • To assess the growing interest in CRAC channel therapeutics.

Main Methods:

  • Patent analysis focusing on CRAC channel inhibition.
  • Review of biological assays and methodologies described in patents.
  • Bibliometric analysis of patent filing trends.

Main Results:

  • Significant increase in patent filings for CRAC channel inhibitors, with ~80% issued after 2010.
  • Identification of various biological methods used to assess CRAC channel activity and inhibition.
  • Demonstration of a rapidly growing commercial and research interest in CRAC channel modulation.

Conclusions:

  • CRAC channel inhibition represents a rapidly advancing field with substantial therapeutic potential.
  • The patent landscape reflects increasing innovation in targeting CRAC channels for disease treatment.
  • Further development of reliable CRAC current measurement and inhibition strategies is evident.